Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151.
Lead Product(s): PRM-151
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,400.0 million Upfront Cash: $390.0 million
Deal Type: Acquisition February 13, 2020